CG MedTech시지메드텍

CG MedTech reported a sharp swing to profit on a 2025 revenue jump, but its trailing numbers are thinner and free cash flow is negative.

CG MedTech runs two businesses: orthopedic and other medical devices, and electricity and heat meters with EV chargers. Revenue rose 36.4% in 2025 to ₩47.2B... more precisely ₩47.2B is shown as ₩47.2B and net income was ₩6.5B, after losses in 2021, 2022 and 2024. On trailing figures to H1 2026, operating margin is 3.7% and free cash flow is -₩22.8B, while the shares fell 13.1% over the past month to ₩5,170.

What stands out

• 2025 revenue was ₩47.2B, up 36.4%, with operating income of ₩3.8B (8.1% margin), a clear step up from the 2024 operating loss.
• Trailing net income of ₩6.6B is well above operating income of ₩1.9B, so a large part of recent profit comes from items outside core operations; the data does not explain them.
• Trailing free cash flow is -₩22.8B against cash of ₩10.3B, and the data does not say how this gap is being funded.
• Valuation is P/E 16.3 and P/B 1.1, below most listed peers shown, though the data gives no forecast to judge whether this is cheap.
• Foreign ownership fell from 3.8% to 3.2% over about 60 days, and foreign and retail investors were net sellers over the last 20 days while institutions bought.

What to watch

• The next half-year or annual results, to see whether operating margin holds above the trailing 3.7% and whether free cash flow turns positive.
• Filings on the recent share consolidation decision and the trading halts in September and October, which the data does not explain.
• Insider and 5%+ holding reports, given recent share-related filings and the stock's 52-week range of about ₩0 to ₩17,775.